WCN26-2806 Efficacy of LDL Apheresis in Inducing Remission in Refractory Minimal Change Nephrotic Syndrome: A Case Series of Four Patients

Read full text Summarise with VIRAT
Authors: Marina Hayashida, Keisuke Osaki, Satoru Kurihara, Yumi Sakaguchi, Kensuke Katsura, Seinosuke Horikawa, Fu Takata, Takaya Handa, Akihiro Yoshimoto
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Minimal change nephrotic syndrome (MCNS) generally responds well to corticosteroid therapy; however, a subset of patients experience refractory or relapsing disease with limited treatment options. Low-density lipoprotein apheresis (LDL-A), initially developed for familial hypercholesterolemia, has been used in Japan since the late 1980s as an adjunctive therapy for refractory focal segmental glomerulosclerosis (FSGS), with favorable clinical outcomes. While LDL-A remains rarely performed internationally, Japanese clinical experience has demonstrated its efficacy, leading to expansion of its health insurance indication in 2024 to include MCNS and membranous nephropathy.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105589–105589
Publication date
25 March 2026
Language
EN